2015—2017年辽宁省肿瘤医院抗肿瘤分子靶向药物的使用情况分析

Analysis on use of anti-tumor molecular targeted drugs of Liaoning Cancer Hospital from 2015 to 2017

目的了解并分析2015—2017年辽宁省肿瘤医院抗肿瘤分子靶向药物的临床应用及用药趋势,为靶向药物的规范管理和合理应用提供参考。方法采用WHO推荐的限定日剂量(DDD)法对2017年2015—2017年辽宁省肿瘤医院门诊麻醉药品的规格、销量、销售金额、用药频度(DDDs)、日均费用(DDC))和排序比(B/A)等进行统计分析。结果门诊用药以小分子靶向药物为主,治疗非小细胞肺癌的吉非替尼、厄洛替尼以及埃克替尼的用量和DDDs相对较高,其他小分子靶向药物排名靠后。住院病房用药以抗体类靶向药物为主,以贝伐珠单抗和曲妥珠单抗的DDDs最高。相对于小分子靶向药物,抗体类靶向药物的DDC普遍偏高。利妥昔单抗(500、100 mg)、西妥昔单抗的B/A连续3年<1.00。埃克替尼、厄洛替尼(150mg)以及吉非替尼的B/A均大于1.00。结论随着对抗肿瘤分子靶向药物认识的逐渐深入,辽宁省肿瘤医院靶向药物的使用情况将更加合理。

Objective To understand and analyze the clinical application and the trend of anti-tumor molecular targeted drugs of Liaoning Cancer Hospital from 2015 to 2017, and provide a reference for the standardized management and reasonable application of targeted drugs. Methods The specifications, sales volume, consumption sum, frequency of drug use(DDDs), defined daily cost(DDC), and drug sequence ratio(B/A) of anti-tumor molecular targeted drugs of Liaoning Cancer Hospital from 2015 to 2017 were analyzed statistically according to the WHO-recommended DDD(defined daily dose) method. Results Most of molecular targeted agents were used in outpatients. DDDs of gefitinib, erbtinib, and icotinib were higher than other molecular targeted agents. Most of monoclonal antibodies were used in inpatients, and DDDs of bevacizumab and trastuzumab were the highest. The DDC ordering of monoclonal antibodies were higher than molecular targeted agents. B/A of rituximab(500 and 100 mg) and cetuximab were lower than 1.00 for three consecutive years. While B/A of icotinib and erlotinib(150 mg) were more than 1.00. Conclusion With the gradual deepening understanding of targeted drugs, the use of targeted drugs in Liaoning Cancer Hospital is more and more reasonable.